Previous close | 3.7000 |
Open | 3.7000 |
Bid | 6.0000 |
Ask | 6.8500 |
Strike | 61.00 |
Expiry date | 2024-05-17 |
Day's range | 3.7000 - 3.7000 |
Contract range | N/A |
Volume | |
Open interest | 8 |
SANTA MONICA, Calif., May 14, 2024--Kite, a Gilead Company (Nasdaq: GILD), today announced 12 abstracts from its industry-leading Chimeric Antigen Receptor (CAR) T-cell therapy portfolio at the upcoming 2024 European Hematology Association (EHA) Annual Congress, June 13-16, Madrid, Spain.
S&P 500 companies have had a solid Q1 earnings season, with one key exception: drugmaker Bristol Myers Squibb.
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.